- $194.29m
- -$2.45m
- $21.05m
Brief: Alector Q1 Basic EPS USD -0.21
Brief: Alector To Discontinue Phase 2 Trial Of Nivisnebart
Alector Q4 net loss widens to $37.3 mln
Brief: Alector Q4 Basic EPS USD -0.34
Clinical biotech firm Alector Q3 revenue beats expectations
Brief: Alector Q3 Basic EPS USD -0.34
U.S. STOCKS ON THE MOVE-Mattel, Alphabet, GE Vernova
U.S. STOCKS ON THE MOVE-Healthcare Services Group, Western Alliance, Warner Bros Discovery
Alector plunges after dementia drug fails to slow disease progression
U.S. STOCKS ON THE MOVE- Avadel Pharma, Amphenol, Applied Digital
U.S. STOCKS ON THE MOVE-Alphabet, Intuitive Surgical, Thermo Fisher
Alector plunges after dementia drug fails to slow disease progression
UK Stocks-Factors to watch on October 22
Alector shares plunge after dementia drug fails to slow disease progression
Brief: Alector Inc - Workforce Reduction Impacts About 75 Employees - SEC Filing
Brief: Alector Announces Topline Results From Latozinemab Phase 3 Trial In Individuals With Frontotemporal Dementia Due To A Grn Mutation And Provides Business Update
Alector Inc reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Alector's Q2 net loss narrows
Alector Inc expected to post a loss of 46 cents a share - Earnings Preview